Infliximab as ultima ratio in a case of refractory non-Crohn’s disease complex fistula system: case report and mini-review of the literature - Takeaways - MDSpire

Infliximab as ultima ratio in a case of refractory non-Crohn’s disease complex fistula system: case report and mini-review of the literature

  • By

  • Nada Agbariah

  • Matthias Kis

  • Christine Manser

  • Luc Biedermann

  • Gerhard Rogler

  • June 16, 2026

  • 0 min

Share

  • 1

    Infliximab (IFX) has been a first-line treatment for perianal fistulizing Crohn’s disease since 1999, but its role in non-CD fistulas is unclear.

  • 2

    A 76-year-old man with recurrent non-CD-related fistulas and sepsis was treated with IFX after failed surgical and endoscopic options.

  • 3

    The patient showed significant clinical improvement within 2 weeks of IFX induction therapy and reported no further hospitalizations at 1-year follow-up.

  • 4

    MRI results indicated a reduction in the size of the presacral wound cavity after 22 weeks of IFX therapy.

  • 5

    This case suggests that IFX may be an effective option for managing non-CD-related fistulas when other treatments fail.

Original Source(s)

Infliximab as ultima ratio in a case of refractory non-Crohn’s disease complex fistula system: case report and mini-review of the literature

  • by Nada Agbariah, Matthias Kis, Christine Manser, Luc Biedermann, Gerhard Rogler

  • June 16, 2026

Related Content

DNA damage response inhibitors in pancreatic cancer: progress and challenges

Correction: Gut microbiota in type 2 diabetes mellitus: mechanistic links between dysbiosis, insulin resistance, and chronic low-grade inflammation

Editorial: Interplay between glucose and lipid homeostasis in metabolic health